BeiGene’s Tislelizumab Achieves Positive Phase II Results

BeiGene, Ltd. achieved positive results from a pivotal Phase II study of tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL).
 
"The encouraging clinical results from this study further support our new drug application for tislelizumab in patients with R/R cHL that is currently under priority review in China," said Jane Huang, M.D., Chief Medical Officer, Hematology, at BeiGene. "We hope that this potentially differentiated anti-PD-1 antibody could become a new treatment option for cancer patients in China and across the world."
 
"Tislelizumab demonstrated high anti-tumor activity in patients with R/R cHL – evidenced by an overall response rate of 87% and a complete response rate of 63%, and was generally well tolerated in these patients," said Yuqin Song, M.D., Ph.D., Associate Professor of Medical Oncology, Deputy Director of the Lymphoma Department at Peking University Cancer Hospital in China, and the presenting author of the study.

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com